Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

BACKGROUND: Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with M...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Park, Se Hoon, Cho, Eun Kyung, Bang, Soo-Mee, Shin, Dong Bok, Lee, Jae Hoon, Lee, Young Don
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2005
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC553982/
https://ncbi.nlm.nih.gov/pubmed/15723709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-5-21
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky